GAITHERSBURG, Md.–(BUSINESS WIRE) October 05, 2018 –Valneva USA, the U.S. subsidiary of global vaccine biotech company Valneva SE, today announced U.S. Food and Drug Administration (FDA) approval of an accelerated dosing regimen for Ixiaro…Original Article
You may also like
FDA Approves Orlynvah (sulopenem etzadroxil and...
U.S. FDA Approves Pfizer’s RSV Vaccine Abrysvo for...
Alvotech and Teva Announce U.S. FDA Approval of...
FDA Approves Vyloy (zolbetuximab-clzb) for the...
Botox Cosmetic (onabotulinumtoxinA) Receives FDA...
FDA Approves Vyalev (foscarbidopa and foslevodopa) for...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.